Promostem®, mesenchymal stem cells for treatment of graft-versus-host disease

Promostem® are human umbilical cord blood-derived mesenchymal stem cells. The applied potency screening technology allows for selection of stem cell batches that are qualified for clinical indications. Early engraftment of transplanted hematopoietic stem cells (HSCs) is key to achieving a successful outcome following hematopoietic stem cell transplantation (HSCT). A failed HSCT is life-threatening because it leads to a high incidence of graft-versus-host Disease (GvHD).